0
     

Report Added
Report already added
Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smallpox - Overview
Smallpox - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Smallpox - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smallpox - Companies Involved in Therapeutics Development
AlphaVax Inc
Bavarian Nordic A/S
BioFactura Inc
EpiVax Inc
HK inno.N Corp
SIGA Technologies Inc
Tonix Pharmaceuticals Holding Corp
Viraze
Smallpox - Drug Profiles
CJ-40011 - Drug Profile
Product Description
Mechanism Of Action
Jynneos - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody for Smallpox - Drug Profile
Product Description
Mechanism Of Action
NIOCH-14 - Drug Profile
Product Description
Mechanism Of Action
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
ST-357 - Drug Profile
Product Description
Mechanism Of Action
tecovirimat - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNX-1200 - Drug Profile
Product Description
Mechanism Of Action
TNX-1800 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TNX-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VIR-002 - Drug Profile
Product Description
Mechanism Of Action
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Mar 02, 2022: SIGA announces start of TPOXX post-exposure prophylactic (“PEP”) clinical trials
Jan 10, 2022: SIGA Technologies receives approval from the European Medicines Agency for tecovirimat
Dec 01, 2021: SIGA announces Health Canada regulatory approval of oral TPOXX
Nov 16, 2021: European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommends approval of tecovirimat
Sep 07, 2021: SIGA CEO to speak at NCT USA Conference September 8, 2021
Jun 11, 2021: Bavarian Nordic assists public health England in response to new cases of Monkeypox
May 04, 2021: SIGA announces New Drug Application filing with FDA for intravenous formulation of TPOXX
Mar 22, 2021: Bavarian nordic receives additional smallpox vaccine order from the Canadian government
Feb 19, 2021: BioFactura funded $13 million contract option for its smallpox biodefense therapeutic
Jan 13, 2021: SIGA Announces Public Health Agency of Canada contract award to purchase up to approximately $33 million of oral TPOXX
Jan 05, 2021: Bavarian Nordic to supply smallpox vaccines to three European countries
Dec 16, 2020: Bavarian Nordic secures second part of Smallpox Vaccine order from the U.S. Government
Dec 04, 2020: Vaccine genome researchers report 99.7% colinear identity between a U.S. civil war era smallpox vaccine and horsepox virus
Nov 12, 2020: SIGA Technologies Chief Scientific Officer to participate at NCT Asia Virtual Conference
Oct 08, 2020: SIGA announces Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Smallpox, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Smallpox - Pipeline by AlphaVax Inc, 2022
Smallpox - Pipeline by Bavarian Nordic A/S, 2022
Smallpox - Pipeline by BioFactura Inc, 2022
Smallpox - Pipeline by EpiVax Inc, 2022
Smallpox - Pipeline by HK inno.N Corp, 2022
Smallpox - Pipeline by SIGA Technologies Inc, 2022
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Smallpox - Pipeline by Viraze, 2022
Smallpox - Dormant Projects, 2022
Smallpox - Dormant Projects, 2022 (Contd..1)
Smallpox - Discontinued Products, 2022

List of Figures
Number of Products under Development for Smallpox, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Smallpox Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

Dental Consumables Market by Product (Dental Implants, Orthodontics, Periodontics, Endodontics, Bridges, Crowns, Dentures, Clear aligners, Disinfectants, Pastes, Cups, Brushes, Accessories), End user (Dental Clinics, Hospitals) - Global Forecast to 2027

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry Analyzers and Reagent Market--Supplier Shares, Forecasts for 55 Tests, Opportunities--Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline